Mitigating TDP-43 protein dysfunction is the aim of a number of novel therapeutic targets in development for ALS, i.e., STMN2 (32), UNC13A (33), eIF2B (34), PIKFYVE (35). This evidence concerns the gene STMN2 and amyotrophic lateral sclerosis.